Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

INTERVIEW: Bridge Chief On Pursuing NRDO, Global Ambitions

Executive Summary

Bridge Biotherapeutics is off to a great start with its recent successful Series A funding, raising the largest amount so far for a South Korean bioventure. The company’s CEO talks to Scrip about where the company is heading including plans for its first-in-class inflammatory bowel disease candidate and further financings.

Advertisement

Related Content

Bridge Bio Eyes Faster Pipeline Progress Through New Funds, Model

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register